Objective: No standard second-line treatment exists for acute graft-versus-host disease steroid-refractory (SR-aGvHD), and long-term outcomes remain poor.
| INTRODUC TI ON
Despite decades of research, acute graft-versus-host disease (aGvHD) is still one of the leading causes of death after haematopoietic allogeneic stem cell transplantation (HSCT) for both paediatric and adult patients. 1, 2 Immunosuppressive therapy with systemic corticosteroids is the first-line treatment option. However, latest available studies estimate that about 50%-70% of the patients do not respond to this therapy. [3] [4] [5] Currently, there is no standard second-line treatment available and outcomes in terms of morbidity and mortality remain poor. [5] [6] [7] [8] [9] Since 2004, mesenchymal stromal cells (MSCs) are increasingly studied in phase II clinical trials as a therapeutic option, demonstrating positive treatment effects for steroid-refractory (SR)-aGvHD. 10, 11 However, most of these trials are single-arm studies or case studies or include a limited amount of patients (<50 participants), making reliable and meaningful conclusions challenging. Ideally, the effectiveness of MSC should be tested through phase III randomised controlled trials (RCTs), but these trials are difficult to perform due to regulatory and patient population-related issues. [11] [12] [13] In 2010, results of one RCT (Prochymal; Osiris Therapeutics, Inc. Columbia, Maryland, United States) were released in the form of an unreviewed abstract. 14 Further, a multicentre RCT is currently being conducted by the European Union Horizon 2020-funded research consortium RETHRIM (REgeneration THRough IMmunomodulation) 15 (ie, the HOVON 113 MSC trial 16 ). The latter study aims to determine the efficacy and cost-effectiveness of MSC as part of a second-line treatment for aGvHD.
In the absence of reliable and conclusive RCT data, several options exist to aggregate and synthesise currently available evidence of MSCs as a treatment option for SR-aGvHD. These include metaanalyses, observational databases, the aggregation of expert opinion or decision analytic modelling. 17 Thus far, four reviews that include currently available trials testing MSC as treatment for SR-aGvHD have been published, [11] [12] [13] 18 of which two are meta-analyses. 11, 18 However, none of the reviews combine available patient-level data (PLD) of the phase II trials to predict and model long-term outcomes of MSC treatment.
The aim of this study was to develop a disease model (DM) to describe the natural history of SR-aGvHD progression and its treatment pathways. The DM can be used to predict long-term outcomes and cost-effectiveness of current (eg, MSC treatment) and future treatment options for SR-aGvHD. To test the practicability of the model, we aimed to gather and implement PLD of a second-line treatment option. Ultimately, our model may facilitate clinical decision-making under conditions of uncertainty. [19] [20] [21] When costs are added, this model can be a valuable tool for reimbursement decision-makers. 
| Model characteristics
The aim of the DM was 2-fold. First, it needed to represent the natural history of SR-aGvHD and its treatment pathways in a simplified manner. Therefore, the DM focusses on the SR-aGvHD only until patients either progress, relapse, develop chronic GvHD or die. Second, it needed to be easily adaptable to a cost-effectiveness model at a later stage. Therefore, the DM was built based on clinical expertise, previously published literature 3, 5, 10, 23, 24 and the RETHRIM protocol 15 . According to the ISPOR recommendations for good modelling practice, 25 we consulted clinical experts to ascertain that the model represents the disease process and addresses the decision problem of determining which one second-line treatment option is (cost-)effective when compared to another therapy option. We employed a convenience sample to include the clinical experts from the RETHRIM consortium. To be part of RETHRIM, consortium members needed to prove extensive research and treatment experience in the field of HSCT and work at a HSCT specialised treatment centre. All experts involved in this research thus have various professional backgrounds (eg, internal medicine, haematology, oncology or transfusion medicine) and originate from five EU member states (Germany, Italy, The
Netherlands, Spain and Sweden). A European perspective on the disease and treatment pathway(s) of SR-aGvHD was hence ensured. 
| Involvement of experts

| Simulation
We ran a base-case simulation with a hypothetical patient cohort comprising 100 patients with aGvHD grades II-IV. Survival was modelled on a lifetime horizon, whereas it was assumed that patients do not exceed the age of 99 years. 27 Health outcomes of the simulation were expressed in life-years (LYs). As future health effects are valued lower than immediate effects, 22 we adjusted future health outcomes (LYs) to "present values" according to the Dutch guideline for economic evaluations in health care. 28, 29 All statistical analyses were conducted in RStudio (version 
| Involvement of experts
The 
| Part 2: Model simulation
| Model input parameters
We detected 18 studies that reported on phase II trials and collection of case studies 4, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] , of which 9 reported PLD [33] [34] [35] [36] [37] [38] 40, 43, 49 (see Appendix S2). Unpublished 4, 42 and additional data 46 were requested and received for three studies. Two studies could be integrated by reconstructing the published Kaplan-Meier curves. 44, 48 Three studies were excluded because they did not publish survival data, 47, 50 or the proportion of patients in the response categories. 41 Patients reported in the study by Ringdén et al 45 were not included as they had been already included in the data presented by Le Blanc and colleagues. 4 
| Transition probabilities for the first two model cycles
Reported mean and median time of first evaluation was 26.6 and 28 days, respectively (range = 2-58). To integrate all available observations into the model, we assumed that all responses were evaluated within the first 28 days after MSC treatment. Based on this, we calculated a transition matrix showing the probability of response to MSC after day 28 (see Table 1 ). 
| Long-term survival estimation
To extrapolate survival estimates beyond study observations, survival data, available for 235 patients (115 CR, 120 nCR), were used. Based on clinical expertise, the lognormal distribution would present the best balance between the statistical tests of fit and visual inspection for both CR and nCR.
| Results of the model simulation
At the 28-day treatment evaluation, of the 100 simulated cases with aGvHD II-IV, approximately 43 and 44 observations had a CR and nCR, respectively. The median survival time modelled for CR was 3.2 and 0.5 years for nCR. Overall median survival for all patients irrespective of their response category was 9.6 months. Average per-person life-years were estimated at 0.32 years (ie, 3.8 months).
In Figure 3 , modelling results are plotted on the empirical KaplanMeier curves for CR and nCR. 
| D ISCUSS I ON
In this study, we present a DM for the second-line treatment of aGvHD. In line with current recommendations for good modelling practice, we involved an international group of clinical experts to develop this DM and used evidence available from the literature. To run a first model simulation, we searched for available evidence on both costs and clinical evidence on treatment alternatives for aGvHD. We found that MSCs for the treatment of SR-aGvHD are widely studied. Therefore, we were able to integrate more than a decade of empirical data into our DM. Nevertheless, mainly due to the absence of randomised phase III studies, the number of patients included and the restricted follow-up periods, we faced several challenges in integrating the collected information. Consequently, we had made a number of assumptions. Third, it needs to be noted that the simulation did not consider the underlying haematological disease, nor the patients' age or sex.
This choice was made as not all studies did report on these variables and any further stratification would have resulted in a reduction in the population on which the different estimates are based. However, we acknowledge that the underlying haematological disease and age and sex can be important determinants for long-term survival.
Detailed reporting on patient characteristics and their diagnosis may help to enable further analyses for these subgroups.
Our modelling results, however, did show the expected longer survival after MSC transfusion for patients that achieved CR at first response evaluation, when compared to patients with nCR. These estimates are in line with previous findings highlighting the importance of complete response for long-term survival. [51] [52] [53] [54] [55] [56] To our knowledge, there are no long-term survival results published for SR-aGvHD patients treated with MSCs other than the two reports 57, 58 that are based on studies 4,45 included in our study. Regarding survival of aGvHD patients treated with ECP, the largest series was published by Greinix et al 54 in a phase II prospective study. 9 Every week, 59 patients with steroid-refractory or steroid-dependent GvHD received two consecutive ECP treatments.
CR and nCR was defined as in our study. The reported median survival was below 6 months after HSCT for patients with nCR, confirming our median survival estimations for nCR to MSC of approximately 6 months. 54 In the study of Greinix et al 54 , median survival for complete responders was never reached during the reported follow-up period of 9 years after HSCT. For this study, this implies that the probability of surviving nine years after HSCT would be approximately 59% for patients with a CR With an estimate of approximately 27% at ten years post-MSCs, our estimates for patients with a CR are significantly lower. This may be explained by differences in patient population before treatment (ie, Greinix et al 54 included a higher number of patients with aGvHD grade II (61%)). In addition, the study by Greinix and colleagues was based on a limited amount of complete responders (n = 41).
Although we were able to demonstrate longer survival for patients with CR when compared to nCR, the relatively high mortality rate of TA B L E 2 Estimated overall survival probability in per cent to speculation and the search for alternative (pre)treatments helping patients to achieve a complete response will have to continue.
| CON CLUS ION
The designed DM provides a comprehensive overview on the sec- 
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